References
- Raghu R , DevarajiV, LeenaKet al. Virtual screening and discovery of novel aurora kinase inhibitors. Curr. Top. Med. Chem.14(17), 2006–2019 (2014).
- Tanase CP , EnciuAM, MihaiS, NeaguAI, CalenicB, CruceruML. Anti-cancer therapies in high grade gliomas. Curr. Proteomics10(3), 246–260 (2013).
- Lacombe D , TejparS, SalgadoRet al. European perspective for effective cancer drug development. Nat. Rev. Clin. Oncol.11(8), 492–498 (2014).
- Hughes JP , ReesS, KalindjianSB, PhilpottKL. Principles of early drug discovery. Br. J. Pharmacol.162(6), 1239–1249 (2011).
- Yarden Y , CaldasC. Basic cancer research is essential for the success of personalised medicine. Eur. J. Cancer49(12), 2619–2620 (2013).
- Janero DR . The future of drug discovery: enabling technologies for enhancing lead characterization and profiling therapeutic potential. Expert Opin. Drug Discov.9(8), 847–858 (2014).
- Roukos DH . Genome network medicine: innovation to overcome huge challenges in cancer therapy. Wiley Interdiscip. Rev. Syst. Biol. Med.6(2), 201–208 (2014).
- Schleifman EB , TamR, PatelRet al. Next generation mut-map, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel. PloS One9(3), e90761 (2014).
- Schiffman FJ . The teaching house officer. Yale J. Biol. Med.59(1), 55–61 (1986).
- Zhang F , DrabierR. Ipad: the integrated pathway analysis database for systematic enrichment analysis. BMC Bioinformatics13(Suppl. 15), S7 (2012).
- Spaet TH. Blood in contact with natural and artificial surfaces. Ann. NY Acad. Sci.516, 1–688 (1987).
- Gillis NK , PatelJN, InnocentiF. Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era. Clin. Pharmacol. Ther.95(3), 269–280 (2014).
- Albulescu R , NeaguM, AlbulescuL, TanaseC. Tissular and soluble mirnas for diagnostic and therapy improvement in digestive tract cancers. Expert Rev. Mol. Diagn.11(1), 101–120 (2011).
- Lynam-Lennon N , MaherSG, ReynoldsJV. The roles of microrna in cancer and apoptosis. Biol. Rev. Camb. Philos. Soc.84(1), 55–71 (2009).
- Zhang B , PanX, CobbGP, AndersonTA. Micrornas as oncogenes and tumor suppressors. Dev. Biol.302(1), 1–12 (2007).
- Adams BD , KasinskiAL, SlackFJ. Aberrant regulation and function of micrornas in cancer. Curr. Biol.24(16), R762–R776 (2014).
- Saumet A , MathelierA, LecellierCH. The potential of micrornas in personalized medicine against cancers. Biomed. Res. Int.2014, 642916 (2014).
- Kar S , RoyK. How far can virtual screening take us in drug discovery?Expert Opin. Drug Discov.8(3), 245–261 (2013).
- Cohen T , WiddowsD, StephanCet al. Predicting high-throughput screening results with scalable literature-based discovery methods. CPT Pharmacometrics Syst. Pharmacol.3, e140 (2014).